KIR2DL3 and Miyoshi myopathy: Furthermore, contrary to the percentage expression of the other inhibitory KIR, CD158b, the MFI of this receptor decreases significantly (p < 0.05, Wilcoxon signed rank test) after 18 h in vitro treatment with combined IL-12 and IL-18 on NK cells and their dim subset in both HC and MM patients.